AU2001273432A1 - Methods and compositions for rapid protein and peptide extraction and isolation using a lysis matrix - Google Patents
Methods and compositions for rapid protein and peptide extraction and isolation using a lysis matrixInfo
- Publication number
- AU2001273432A1 AU2001273432A1 AU2001273432A AU7343201A AU2001273432A1 AU 2001273432 A1 AU2001273432 A1 AU 2001273432A1 AU 2001273432 A AU2001273432 A AU 2001273432A AU 7343201 A AU7343201 A AU 7343201A AU 2001273432 A1 AU2001273432 A1 AU 2001273432A1
- Authority
- AU
- Australia
- Prior art keywords
- protein
- matrix
- cell
- molecules
- peptide molecules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000623 proteins and genes Proteins 0.000 title claims description 410
- 102000004169 proteins and genes Human genes 0.000 title claims description 409
- 239000011159 matrix material Substances 0.000 title claims description 305
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 279
- 239000000203 mixture Substances 0.000 title claims description 175
- 238000000034 method Methods 0.000 title claims description 168
- 230000009089 cytolysis Effects 0.000 title claims description 93
- 238000002955 isolation Methods 0.000 title description 24
- 238000000605 extraction Methods 0.000 title description 11
- 210000004027 cell Anatomy 0.000 claims description 171
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 77
- 230000001413 cellular effect Effects 0.000 claims description 63
- 239000011148 porous material Substances 0.000 claims description 52
- 239000011347 resin Substances 0.000 claims description 48
- 229920005989 resin Polymers 0.000 claims description 48
- 150000001875 compounds Chemical class 0.000 claims description 44
- 239000003153 chemical reaction reagent Substances 0.000 claims description 37
- 239000012528 membrane Substances 0.000 claims description 34
- 230000008823 permeabilization Effects 0.000 claims description 32
- 102000004190 Enzymes Human genes 0.000 claims description 31
- 108090000790 Enzymes Proteins 0.000 claims description 31
- 229940088598 enzyme Drugs 0.000 claims description 31
- 108020004707 nucleic acids Proteins 0.000 claims description 28
- 102000039446 nucleic acids Human genes 0.000 claims description 28
- 150000007523 nucleic acids Chemical class 0.000 claims description 28
- 239000007787 solid Substances 0.000 claims description 25
- 230000006037 cell lysis Effects 0.000 claims description 23
- 239000000758 substrate Substances 0.000 claims description 23
- 239000003599 detergent Substances 0.000 claims description 21
- 239000012634 fragment Substances 0.000 claims description 21
- 230000001580 bacterial effect Effects 0.000 claims description 17
- -1 polyethylene Polymers 0.000 claims description 15
- 239000004202 carbamide Substances 0.000 claims description 12
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 12
- 241000588724 Escherichia coli Species 0.000 claims description 10
- 102000016943 Muramidase Human genes 0.000 claims description 10
- 108010014251 Muramidase Proteins 0.000 claims description 10
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 10
- 239000003446 ligand Substances 0.000 claims description 9
- 229960000274 lysozyme Drugs 0.000 claims description 9
- 239000004325 lysozyme Substances 0.000 claims description 9
- 235000010335 lysozyme Nutrition 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 210000004102 animal cell Anatomy 0.000 claims description 6
- 210000005253 yeast cell Anatomy 0.000 claims description 6
- 239000004698 Polyethylene Substances 0.000 claims description 5
- 229920002301 cellulose acetate Polymers 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 5
- 229920000728 polyester Polymers 0.000 claims description 5
- 229920000573 polyethylene Polymers 0.000 claims description 5
- 239000000020 Nitrocellulose Substances 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 4
- 239000003708 ampul Substances 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 239000012535 impurity Substances 0.000 claims description 4
- 229920001220 nitrocellulos Polymers 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 108090000988 Lysostaphin Proteins 0.000 claims description 3
- 239000004677 Nylon Substances 0.000 claims description 3
- 230000002538 fungal effect Effects 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 229920001778 nylon Polymers 0.000 claims description 3
- 229920000098 polyolefin Polymers 0.000 claims description 3
- 108010082737 zymolyase Proteins 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 239000006172 buffering agent Substances 0.000 claims description 2
- 239000000919 ceramic Substances 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 229910017053 inorganic salt Inorganic materials 0.000 claims 1
- 238000000746 purification Methods 0.000 description 56
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 38
- 108020004414 DNA Proteins 0.000 description 34
- 239000000872 buffer Substances 0.000 description 31
- 230000027455 binding Effects 0.000 description 26
- 238000005516 engineering process Methods 0.000 description 25
- 210000003000 inclusion body Anatomy 0.000 description 25
- 239000011324 bead Substances 0.000 description 24
- 239000000499 gel Substances 0.000 description 23
- 238000000926 separation method Methods 0.000 description 23
- 238000000527 sonication Methods 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 238000010828 elution Methods 0.000 description 20
- 239000000463 material Substances 0.000 description 20
- 239000011780 sodium chloride Substances 0.000 description 19
- 239000001488 sodium phosphate Substances 0.000 description 18
- 229910000162 sodium phosphate Inorganic materials 0.000 description 18
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 18
- 210000002421 cell wall Anatomy 0.000 description 16
- 238000000751 protein extraction Methods 0.000 description 15
- 230000002934 lysing effect Effects 0.000 description 14
- 229920000936 Agarose Polymers 0.000 description 13
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 210000000170 cell membrane Anatomy 0.000 description 12
- 102000037865 fusion proteins Human genes 0.000 description 12
- 108020001507 fusion proteins Proteins 0.000 description 12
- 239000008188 pellet Substances 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 238000005119 centrifugation Methods 0.000 description 11
- 238000001914 filtration Methods 0.000 description 11
- 238000011534 incubation Methods 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 11
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 230000010261 cell growth Effects 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 9
- 239000000356 contaminant Substances 0.000 description 9
- 239000002198 insoluble material Substances 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 8
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 8
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 8
- 238000005063 solubilization Methods 0.000 description 8
- 230000007928 solubilization Effects 0.000 description 8
- 239000011543 agarose gel Substances 0.000 description 7
- 230000002209 hydrophobic effect Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 229910019142 PO4 Inorganic materials 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000012149 elution buffer Substances 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000012139 lysis buffer Substances 0.000 description 6
- 229920002521 macromolecule Polymers 0.000 description 6
- 229910052759 nickel Inorganic materials 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
- 239000010452 phosphate Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 5
- 238000001261 affinity purification Methods 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 5
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 5
- 229960005542 ethidium bromide Drugs 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- MASIZQYHVMQQKI-OIIXUNCGSA-N (2r,3r,4s,5s,6r)-2-[(2r,3s,4r,5r,6r)-4,5-dihydroxy-2-(hydroxymethyl)-6-octoxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 MASIZQYHVMQQKI-OIIXUNCGSA-N 0.000 description 4
- ZWEVPYNPHSPIFU-UHFFFAOYSA-N 2,3,4,5,6-pentahydroxy-n-[3-[3-(2,3,4,5,6-pentahydroxyhexanoylamino)propyl-[4-(3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl)pentanoyl]amino]propyl]hexanamide Chemical compound OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)N(CCCNC(=O)C(O)C(O)C(O)C(O)CO)CCCNC(=O)C(O)C(O)C(O)C(O)CO)C)C1(C)C(O)C2 ZWEVPYNPHSPIFU-UHFFFAOYSA-N 0.000 description 4
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 4
- 108010024636 Glutathione Proteins 0.000 description 4
- 108010083644 Ribonucleases Proteins 0.000 description 4
- 102000006382 Ribonucleases Human genes 0.000 description 4
- BHTRKEVKTKCXOH-UHFFFAOYSA-N Taurochenodesoxycholsaeure Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)CC2 BHTRKEVKTKCXOH-UHFFFAOYSA-N 0.000 description 4
- 229920004890 Triton X-100 Polymers 0.000 description 4
- 239000013504 Triton X-100 Substances 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 239000013611 chromosomal DNA Substances 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 229960003180 glutathione Drugs 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- HEGSGKPQLMEBJL-UHFFFAOYSA-N n-octyl beta-D-glucopyranoside Natural products CCCCCCCCOC1OC(CO)C(O)C(O)C1O HEGSGKPQLMEBJL-UHFFFAOYSA-N 0.000 description 4
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000012474 protein marker Substances 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 230000003381 solubilizing effect Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 235000012431 wafers Nutrition 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 102100031780 Endonuclease Human genes 0.000 description 3
- 108010042407 Endonucleases Proteins 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 229960003964 deoxycholic acid Drugs 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000003365 glass fiber Substances 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 3
- 230000003100 immobilizing effect Effects 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- 239000003456 ion exchange resin Substances 0.000 description 3
- 229920003303 ion-exchange polymer Polymers 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 150000002605 large molecules Chemical class 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000010008 shearing Methods 0.000 description 3
- WUCWJXGMSXTDAV-QKMCSOCLSA-N (2r,3r,4s,5s,6r)-2-[(2r,3s,4r,5r,6r)-6-(6-cyclohexylhexoxy)-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@@H](OCCCCCCC2CCCCC2)[C@H](O)[C@H]1O WUCWJXGMSXTDAV-QKMCSOCLSA-N 0.000 description 2
- JVAZJLFFSJARQM-RMPHRYRLSA-N (2r,3r,4s,5s,6r)-2-hexoxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound CCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JVAZJLFFSJARQM-RMPHRYRLSA-N 0.000 description 2
- QFAPUKLCALRPLH-UXXRCYHCSA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-nonoxyoxane-3,4,5-triol Chemical compound CCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QFAPUKLCALRPLH-UXXRCYHCSA-N 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 2
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 2
- SIDULKZCBGMXJL-UHFFFAOYSA-N 1-dimethylphosphoryldodecane Chemical compound CCCCCCCCCCCCP(C)(C)=O SIDULKZCBGMXJL-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 2
- GUQQBLRVXOUDTN-XOHPMCGNSA-N 3-[dimethyl-[3-[[(4r)-4-[(3r,5s,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]propyl]azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CC(O)CS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 GUQQBLRVXOUDTN-XOHPMCGNSA-N 0.000 description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 239000004380 Cholic acid Substances 0.000 description 2
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 2
- 241000588722 Escherichia Species 0.000 description 2
- 108091006057 GST-tagged proteins Proteins 0.000 description 2
- 108010007979 Glycocholic Acid Proteins 0.000 description 2
- 108010035713 Glycodeoxycholic Acid Proteins 0.000 description 2
- WVULKSPCQVQLCU-UHFFFAOYSA-N Glycodeoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 WVULKSPCQVQLCU-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 2
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- JVAZJLFFSJARQM-UHFFFAOYSA-N O-n-hexyl beta-D-glucopyranoside Natural products CCCCCCOC1OC(CO)C(O)C(O)C1O JVAZJLFFSJARQM-UHFFFAOYSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 241000607720 Serratia Species 0.000 description 2
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 241000187747 Streptomyces Species 0.000 description 2
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 2
- UBDJSBRKNHQFPD-PYGYYAGESA-N Taurodehydrocholic acid Chemical compound C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C UBDJSBRKNHQFPD-PYGYYAGESA-N 0.000 description 2
- XPIVOYOQXKNYHA-RGDJUOJXSA-N [(2r,3s,4s,5r,6s)-3,4,5-trihydroxy-6-methoxyoxan-2-yl]methyl n-heptylcarbamate Chemical compound CCCCCCCNC(=O)OC[C@H]1O[C@H](OC)[C@H](O)[C@@H](O)[C@@H]1O XPIVOYOQXKNYHA-RGDJUOJXSA-N 0.000 description 2
- AWSYOWHJNGZJGU-OASARBKBSA-N [(2r,3s,4s,5s)-3,4-dihydroxy-5-(hydroxymethyl)-5-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octanoate Chemical compound O[C@H]1[C@H](O)[C@@H](COC(=O)CCCCCCC)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 AWSYOWHJNGZJGU-OASARBKBSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000005415 bioluminescence Methods 0.000 description 2
- 230000029918 bioluminescence Effects 0.000 description 2
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 2
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- 229960002471 cholic acid Drugs 0.000 description 2
- 235000019416 cholic acid Nutrition 0.000 description 2
- 239000012539 chromatography resin Substances 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- WOQQAWHSKSSAGF-WXFJLFHKSA-N decyl beta-D-maltopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 WOQQAWHSKSSAGF-WXFJLFHKSA-N 0.000 description 2
- GSVLCKASFMVUSW-UHFFFAOYSA-N decyl(dimethyl)phosphine oxide Chemical compound CCCCCCCCCCP(C)(C)=O GSVLCKASFMVUSW-UHFFFAOYSA-N 0.000 description 2
- 229940009976 deoxycholate Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 2
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 2
- NLEBIOOXCVAHBD-QKMCSOCLSA-N dodecyl beta-D-maltoside Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLEBIOOXCVAHBD-QKMCSOCLSA-N 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 2
- 229940099347 glycocholic acid Drugs 0.000 description 2
- WVULKSPCQVQLCU-BUXLTGKBSA-N glycodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 WVULKSPCQVQLCU-BUXLTGKBSA-N 0.000 description 2
- XBSQTYHEGZTYJE-OETIFKLTSA-N glycolithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)CC1 XBSQTYHEGZTYJE-OETIFKLTSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- HPEGNLMTTNTJSP-LBELIVKGSA-N heptyl 1-thiohexopyranoside Chemical compound CCCCCCCS[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HPEGNLMTTNTJSP-LBELIVKGSA-N 0.000 description 2
- NIDYWHLDTIVRJT-UJPOAAIJSA-N heptyl-β-d-glucopyranoside Chemical compound CCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NIDYWHLDTIVRJT-UJPOAAIJSA-N 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- PYIDGJJWBIBVIA-UYTYNIKBSA-N lauryl glucoside Chemical compound CCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PYIDGJJWBIBVIA-UYTYNIKBSA-N 0.000 description 2
- IZWSFJTYBVKZNK-UHFFFAOYSA-N lauryl sulfobetaine Chemical compound CCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O IZWSFJTYBVKZNK-UHFFFAOYSA-N 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 108010056929 lyticase Proteins 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- JVAZJLFFSJARQM-YBXAARCKSA-N n-Hexyl-beta-D-glucopyranoside Natural products CCCCCCO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JVAZJLFFSJARQM-YBXAARCKSA-N 0.000 description 2
- XEPXGZZWVKNRGS-GQYPCLOQSA-N n-[(3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]octanamide Chemical compound CCCCCCCC(=O)NC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XEPXGZZWVKNRGS-GQYPCLOQSA-N 0.000 description 2
- UMWKZHPREXJQGR-UHFFFAOYSA-N n-methyl-n-(2,3,4,5,6-pentahydroxyhexyl)decanamide Chemical compound CCCCCCCCCC(=O)N(C)CC(O)C(O)C(O)C(O)CO UMWKZHPREXJQGR-UHFFFAOYSA-N 0.000 description 2
- GCRLIVCNZWDCDE-SJXGUFTOSA-N n-methyl-n-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]nonanamide Chemical compound CCCCCCCCC(=O)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO GCRLIVCNZWDCDE-SJXGUFTOSA-N 0.000 description 2
- SBWGZAXBCCNRTM-CTHBEMJXSA-N n-methyl-n-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]octanamide Chemical compound CCCCCCCC(=O)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO SBWGZAXBCCNRTM-CTHBEMJXSA-N 0.000 description 2
- CGVLVOOFCGWBCS-RGDJUOJXSA-N n-octyl β-d-thioglucopyranoside Chemical compound CCCCCCCCS[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CGVLVOOFCGWBCS-RGDJUOJXSA-N 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 238000000053 physical method Methods 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 230000000979 retarding effect Effects 0.000 description 2
- 108700004121 sarkosyl Proteins 0.000 description 2
- BHTRKEVKTKCXOH-AYSJQVDDSA-N taurochenodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)C1C2C2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-AYSJQVDDSA-N 0.000 description 2
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 2
- QBYUNVOYXHFVKC-GBURMNQMSA-N taurolithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 QBYUNVOYXHFVKC-GBURMNQMSA-N 0.000 description 2
- BHTRKEVKTKCXOH-LBSADWJPSA-N tauroursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-LBSADWJPSA-N 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- YZNNXXWNKQOETJ-HYLFJBCQSA-N (2r,3r,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-decylsulfanyl-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](SCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YZNNXXWNKQOETJ-HYLFJBCQSA-N 0.000 description 1
- BDOYKFSQFYNPKF-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;sodium Chemical compound [Na].[Na].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O BDOYKFSQFYNPKF-UHFFFAOYSA-N 0.000 description 1
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000589158 Agrobacterium Species 0.000 description 1
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 241000589968 Borrelia Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241001468185 Caryophanon Species 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- 101710172503 Chemokine-binding protein Proteins 0.000 description 1
- 102000012286 Chitinases Human genes 0.000 description 1
- 108010022172 Chitinases Proteins 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- FCKYPQBAHLOOJQ-UHFFFAOYSA-N Cyclohexane-1,2-diaminetetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)C1CCCCC1N(CC(O)=O)CC(O)=O FCKYPQBAHLOOJQ-UHFFFAOYSA-N 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010058683 Immobilized Proteins Proteins 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 101710138270 PspA protein Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000589180 Rhizobium Species 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 241000256248 Spodoptera Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 108010011834 Streptolysins Proteins 0.000 description 1
- 239000008049 TAE buffer Substances 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 210000003763 chloroplast Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 108010049705 endonuclease R Proteins 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 108010009719 mutanolysin Proteins 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000003094 perturbing effect Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- LHBNLZDGIPPZLL-UHFFFAOYSA-K praseodymium(iii) chloride Chemical compound Cl[Pr](Cl)Cl LHBNLZDGIPPZLL-UHFFFAOYSA-K 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000003257 protein preparation method Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 238000010977 unit operation Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/281—Sorbents specially adapted for preparative, analytical or investigative chromatography
- B01J20/282—Porous sorbents
- B01J20/285—Porous sorbents based on polymers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
- B01J20/28054—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their surface properties or porosity
- B01J20/28078—Pore diameter
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/281—Sorbents specially adapted for preparative, analytical or investigative chromatography
- B01J20/286—Phases chemically bonded to a substrate, e.g. to silica or to polymers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
- B01J20/3204—Inorganic carriers, supports or substrates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
- B01J20/3206—Organic carriers, supports or substrates
- B01J20/3208—Polymeric carriers, supports or substrates
- B01J20/321—Polymeric carriers, supports or substrates consisting of a polymer obtained by reactions involving only carbon to carbon unsaturated bonds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
- B01J20/3206—Organic carriers, supports or substrates
- B01J20/3208—Polymeric carriers, supports or substrates
- B01J20/3212—Polymeric carriers, supports or substrates consisting of a polymer obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3234—Inorganic material layers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
- B01J20/3244—Non-macromolecular compounds
- B01J20/3246—Non-macromolecular compounds having a well defined chemical structure
- B01J20/3248—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
- B01J20/3244—Non-macromolecular compounds
- B01J20/3246—Non-macromolecular compounds having a well defined chemical structure
- B01J20/3248—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such
- B01J20/3251—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such comprising at least two different types of heteroatoms selected from nitrogen, oxygen or sulphur
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
- B01J20/3244—Non-macromolecular compounds
- B01J20/3246—Non-macromolecular compounds having a well defined chemical structure
- B01J20/3248—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such
- B01J20/3253—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such comprising a cyclic structure not containing any of the heteroatoms nitrogen, oxygen or sulfur, e.g. aromatic structures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
- B01J20/3268—Macromolecular compounds
- B01J20/327—Polymers obtained by reactions involving only carbon to carbon unsaturated bonds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
- B01J20/3268—Macromolecular compounds
- B01J20/3272—Polymers obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds
- B01J20/3274—Proteins, nucleic acids, polysaccharides, antibodies or antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
- C12M47/06—Hydrolysis; Cell lysis; Extraction of intracellular or cell wall material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/06—Lysis of microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/60—Construction of the column
- G01N30/6052—Construction of the column body
- G01N30/6065—Construction of the column body with varying cross section
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/60—Construction of the column
- G01N30/6091—Cartridges
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Water Supply & Treatment (AREA)
- Inorganic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- General Physics & Mathematics (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Sustainable Development (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21808100P | 2000-07-13 | 2000-07-13 | |
| US60218081 | 2000-07-13 | ||
| US27463001P | 2001-03-12 | 2001-03-12 | |
| US60274630 | 2001-03-12 | ||
| PCT/US2001/022080 WO2002006456A1 (fr) | 2000-07-13 | 2001-07-13 | Methodes et compositions d'extraction et d'isolation rapides de proteines et de peptides au moyen d'une matrice de lyse |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001273432A1 true AU2001273432A1 (en) | 2002-01-30 |
Family
ID=26912535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001273432A Abandoned AU2001273432A1 (en) | 2000-07-13 | 2001-07-13 | Methods and compositions for rapid protein and peptide extraction and isolation using a lysis matrix |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20020012982A1 (fr) |
| EP (1) | EP1301591A4 (fr) |
| JP (1) | JP2004504330A (fr) |
| AU (1) | AU2001273432A1 (fr) |
| CA (1) | CA2415713A1 (fr) |
| NZ (1) | NZ523831A (fr) |
| WO (1) | WO2002006456A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111818980A (zh) * | 2018-03-08 | 2020-10-23 | 生物辐射实验室股份有限公司 | 阴离子交换-疏水混合模式色谱树脂 |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8563232B2 (en) | 2000-09-12 | 2013-10-22 | Lifenet Health | Process for devitalizing soft-tissue engineered medical implants, and devitalized soft-tissue medical implants produced |
| US20080077251A1 (en) * | 1999-06-07 | 2008-03-27 | Chen Silvia S | Cleaning and devitalization of cartilage |
| WO2002065125A1 (fr) * | 2001-02-13 | 2002-08-22 | Invitrogen Corporation | Procedes et compositions utilises dans l'isolation de macromolecules biologiques |
| WO2003025156A2 (fr) * | 2001-09-18 | 2003-03-27 | Affinium Pharmaceuticals, Inc. | Procedes et appareils de purification |
| US7923431B2 (en) * | 2001-12-21 | 2011-04-12 | Ferrosan Medical Devices A/S | Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis |
| US20050079526A1 (en) * | 2002-02-20 | 2005-04-14 | Affinium Pharmaceuticals, Inc. | Methods and apparatuses for characterizing refolding and aggregation of biological molecules |
| CA2477021A1 (fr) * | 2002-02-20 | 2003-08-28 | Affinium Pharmaceuticals, Inc. | Methodes et dispositifs destines a caracteriser la stabilite de molecules biologiques |
| US20040121445A1 (en) * | 2002-07-31 | 2004-06-24 | Fabien Marino | Cell cultures |
| JP2006507818A (ja) | 2002-11-01 | 2006-03-09 | プロメガ コーポレイション | 細胞溶解のための組成物、使用方法、装置およびキット |
| CA2509914A1 (fr) * | 2002-12-11 | 2004-06-24 | Ferrosan A/S | Tampons a prelevements a base de gelatine |
| US20040180445A1 (en) * | 2003-03-12 | 2004-09-16 | Domanico Michael J. | Methods and compositions for purification of nucleic acid from a host cell |
| CA2524393A1 (fr) * | 2003-05-02 | 2004-11-18 | Sigma-Aldrich Co. | Lyse cellulaire a phase solide et plaque de saisie |
| EP2216415B2 (fr) * | 2003-08-01 | 2017-01-04 | Life Technologies Corporation | Compositions et procédés de préparation de courtes molécules d'ARN et d'autres acides nucléiques |
| JP2005095160A (ja) * | 2003-08-19 | 2005-04-14 | Fuji Photo Film Co Ltd | 抽出装置用ラック |
| WO2005072700A2 (fr) * | 2004-01-30 | 2005-08-11 | Ferrosan A/S | Pulverisations et compositions hemostatiques |
| JP4959557B2 (ja) * | 2004-07-09 | 2012-06-27 | フェロサン メディカル デバイシーズ エイ/エス | ヒアルロン酸含有止血合成剤 |
| WO2006020868A2 (fr) * | 2004-08-13 | 2006-02-23 | New England Biolabs, Inc. | Production intracellulaire d'une a nuclease |
| WO2006026248A1 (fr) * | 2004-08-25 | 2006-03-09 | Sigma-Aldrich Co. | Compositions et procedes faisant appel a des combinaisons de detergents zwitterioniques |
| WO2006034009A2 (fr) * | 2004-09-20 | 2006-03-30 | Sigma-Aldrich Co. | Procede d'epuration permettant de debarrasser des biomolecules d'acides nucleiques intacts contaminants |
| GB0423485D0 (en) * | 2004-10-22 | 2004-11-24 | First Water Ltd | Absorbent materials and articles |
| US20060105391A1 (en) * | 2004-11-12 | 2006-05-18 | Promega Corporation | Device and method for separating molecules |
| US20060105349A1 (en) * | 2004-11-12 | 2006-05-18 | Promega Corporation | Device and method for purification of biological materials |
| WO2006064512A1 (fr) * | 2004-12-13 | 2006-06-22 | Unichem Laboratories Limited | Procédé de fractionnement et de stockage de protéines |
| US20060183889A1 (en) * | 2005-01-04 | 2006-08-17 | Bogoev Roumen A | Alkyl phosphine detergent products and extraction processes |
| EP1841854A4 (fr) * | 2005-01-27 | 2009-10-21 | Applera Corp | Dispositifs et procedes de preparation d'echantillons |
| GB0522193D0 (en) * | 2005-10-31 | 2005-12-07 | Axis Shield Asa | Method |
| US8003369B2 (en) | 2005-11-29 | 2011-08-23 | Sanyo Chemical Industries, Ltd. | Bacteriolytic agent |
| US7754429B2 (en) | 2006-10-06 | 2010-07-13 | Illumina Cambridge Limited | Method for pair-wise sequencing a plurity of target polynucleotides |
| EP1939212A1 (fr) * | 2006-12-20 | 2008-07-02 | LEK Pharmaceuticals D.D. | Composés organiques |
| EP1938756A1 (fr) * | 2006-12-29 | 2008-07-02 | Qiagen GmbH | Procédure et matériaux destinés à la libération contrôlée d'une probe biologique |
| US20080300397A1 (en) * | 2007-05-31 | 2008-12-04 | Ge Healthcare Uk Limited | Modified spin column for simple and rapid plasmid dna extraction |
| US9744043B2 (en) | 2007-07-16 | 2017-08-29 | Lifenet Health | Crafting of cartilage |
| JP5215677B2 (ja) | 2008-01-21 | 2013-06-19 | 倉敷紡績株式会社 | 多孔質フィルターカートリッジ |
| DE602008002545D1 (de) * | 2008-02-01 | 2010-10-28 | Eppendorf Ag | Kulturplatte mit Klappe zur seitlichen Belüftung |
| US8642831B2 (en) * | 2008-02-29 | 2014-02-04 | Ferrosan Medical Devices A/S | Device for promotion of hemostasis and/or wound healing |
| US20110044968A1 (en) * | 2008-03-10 | 2011-02-24 | Pharmal N Corporation | Compositions for treatment with metallopeptidases, methods of making and using the same |
| BRPI0903708A2 (pt) * | 2008-06-13 | 2015-06-30 | Yamaha Motor Co Ltd | Motor de combustão interna, veículo, embarcação marítima, e método de purificação de gás de descarga para motor de combustão interna |
| KR101005924B1 (ko) * | 2008-06-27 | 2011-01-06 | 포항공과대학교 산학협력단 | 핵산 추출 장치 |
| WO2012016720A1 (fr) * | 2010-08-05 | 2012-02-09 | Vibod Gmbh | Colonnes inédites utilisables en vue de l'incubation et de l'isolement d'échantillons chimiques et/ou biologiques |
| IL267585B (en) * | 2011-12-22 | 2022-09-01 | Genentech Inc | Ion exchange membrane chromatography |
| CA2865349C (fr) | 2012-03-06 | 2021-07-06 | Ferrosan Medical Devices A/S | Recipient mis sous pression contenant de la pate hemostatique |
| EP2825216B1 (fr) | 2012-06-12 | 2015-08-19 | Ferrosan Medical Devices A/S | Composition hémostatique sèche |
| BR112015005937A2 (pt) | 2012-09-17 | 2017-07-04 | Grace W R & Co | meios e dispositivos cromatográficos |
| RU2015114177A (ru) | 2012-09-17 | 2016-11-10 | У.Р. Грейс Энд Ко.-Конн. | Функционализированный, состоящий из частиц материал носителя и способы его получения и применения |
| AU2014283170B2 (en) | 2013-06-21 | 2017-11-02 | Ferrosan Medical Devices A/S | Vacuum expanded dry composition and syringe for retaining same |
| KR101507234B1 (ko) * | 2013-07-17 | 2015-03-31 | 로레알 | 생분자 추출기 및 생분자 추출방법 |
| RU2678592C1 (ru) | 2013-12-11 | 2019-01-30 | Ферросан Медикал Дивайсиз А/С | Сухая композиция, содержащая компонент, улучшающий экструзию |
| ES2887110T3 (es) | 2014-01-16 | 2021-12-21 | Grace W R & Co | Medios para cromatografía de afinidad y dispositivos para cromatografía |
| WO2015168342A1 (fr) * | 2014-04-29 | 2015-11-05 | Accudx Corporation | Nouvelle matrice d'affinité et dispositifs pour l'isolement et la purification d'arn et d'adn pour des dispositifs moléculaires de point de soin |
| US11389783B2 (en) | 2014-05-02 | 2022-07-19 | W.R. Grace & Co.-Conn. | Functionalized support material and methods of making and using functionalized support material |
| BR112017007466B1 (pt) | 2014-10-13 | 2021-03-02 | Ferrosan Medical Devices A/S | método para preparar uma composição seca, método para reconstituir a composição seca, pasta, composição seca, recipiente, kit homeostático, e, uso de uma composição seca |
| BR112017013565B1 (pt) | 2014-12-24 | 2021-12-28 | Ferrosan Medical Devices A/S | Seringa para retenção e mistura de primeira e segunda substâncias |
| PL3302784T3 (pl) | 2015-06-05 | 2022-01-17 | W.R. Grace & Co.-Conn. | Adsorbentowe środki klarujące do bioprzetwarzania oraz sposoby ich wytwarzania i stosowania |
| RU2717356C2 (ru) | 2015-07-03 | 2020-03-23 | Ферросан Медикал Дивайсиз А/С | Шприц для удерживания вакуума в состоянии хранения |
| CN104928176B (zh) * | 2015-07-16 | 2017-03-08 | 中南大学湘雅医院 | 含组织固定及多层滤过装置的原代肝细胞分离系统及方法 |
| CN104946528A (zh) * | 2015-07-16 | 2015-09-30 | 中南大学湘雅医院 | 一种原代肝组织细胞分离系统及分离方法 |
| WO2017069781A1 (fr) * | 2015-10-23 | 2017-04-27 | Life Technologies Corporation | Système et procédé à base de filtre pour la capture et la lyse efficaces de cellules en suspension |
| US9758755B2 (en) | 2015-10-23 | 2017-09-12 | Life Technologies Corporation | Filter-based method for efficient capture of lysis of suspended cells |
| US10863737B2 (en) * | 2017-05-22 | 2020-12-15 | Drobot Biotechnology Limited Company | Culture container, and system and method of transferring a cultured organism between culture containers |
| CN107058075B (zh) * | 2017-06-20 | 2023-10-20 | 商丘师范学院 | 一种植物细胞原生质体纯化仪及纯化方法 |
| CN107880114B (zh) * | 2017-12-13 | 2020-12-29 | 国药肽谷有限公司 | 一种牛骨胶原蛋白肽生产设备 |
| KR20210008479A (ko) | 2018-05-09 | 2021-01-22 | 훼로산 메디칼 디바이스 에이/에스 | 지혈 조성물을 제조하는 방법 |
| CN112188862A (zh) | 2018-05-22 | 2021-01-05 | 斯特雷拉生物技术股份有限公司 | 乙烯受体生物传感器 |
| JP2023517157A (ja) | 2020-03-09 | 2023-04-24 | イルミナ,インコーポレイテッド | ポリヌクレオチドを配列決定するための方法 |
| US20240263229A1 (en) | 2021-12-16 | 2024-08-08 | Illumina, Inc. | Hybrid clustering |
| EP4448797A1 (fr) | 2021-12-17 | 2024-10-23 | Illumina, Inc. | Hybridation orthogonale |
| EP4493721A1 (fr) | 2022-03-15 | 2025-01-22 | Illumina, Inc. | Séquençage d'échantillons et d'indices parallèles |
| WO2023175037A2 (fr) | 2022-03-15 | 2023-09-21 | Illumina, Inc. | Séquençage simultané de brins de complément avant et inverse sur des polynucléotides séparés pour la détection de méthylation |
| US20230348973A1 (en) | 2022-03-31 | 2023-11-02 | Illumina Cambridge Limited | Paired-end re-synthesis using blocked p5 primers |
| EP4590854A1 (fr) | 2022-09-19 | 2025-07-30 | Illumina, Inc. | Polymères déformables comprenant des amorces immobilisées |
| US20240102067A1 (en) | 2022-09-26 | 2024-03-28 | Illumina, Inc. | Resynthesis Kits and Methods |
| US20240110234A1 (en) | 2022-09-30 | 2024-04-04 | Illumina, Inc. | Amplification Compositions and Methods |
| US20240110221A1 (en) | 2022-09-30 | 2024-04-04 | Illumina, Inc. | Methods of modulating clustering kinetics |
| US20240124914A1 (en) | 2022-09-30 | 2024-04-18 | Illumina, Inc. | Thermophilic compositions for nucleic acid amplification |
| US20240124929A1 (en) | 2022-09-30 | 2024-04-18 | Illumina, Inc. | Mesophilic compositions for nucleic acid amplification |
| WO2024123917A1 (fr) | 2022-12-07 | 2024-06-13 | Illumina, Inc. | Regroupement monoclonal par exclusion stérique d'adn double brin avec ensemencement à motifs |
| CN116606897B (zh) * | 2023-06-05 | 2023-11-21 | 意润健康产业(广州)有限公司 | 一种基于超滤技术的高纯度骨肽及其酶解制备系统 |
| WO2024256581A1 (fr) | 2023-06-14 | 2024-12-19 | Illumina, Inc. | Identification de cytosines modifiées |
| WO2024256580A1 (fr) | 2023-06-14 | 2024-12-19 | Illumina, Inc. | Séquençage simultané avec des anneaux spatialement séparés |
| CN117074590B (zh) * | 2023-08-25 | 2025-10-31 | 中国科学院生态环境研究中心 | 凝胶电泳耦合液相色谱-质谱联用的dna修饰检测方法 |
| WO2025062001A1 (fr) | 2023-09-20 | 2025-03-27 | Illumina, Inc. | Séquençage optimisé d'acides nucléiques |
| WO2025062002A1 (fr) | 2023-09-20 | 2025-03-27 | Illumina, Inc. | Séquençage simultané à l'aide d'une traduction de coupure simple brin |
| WO2025072683A1 (fr) | 2023-09-29 | 2025-04-03 | Illumina, Inc. | Supports solides et procédés pour l'amplification par invasion de brin |
| WO2025137479A1 (fr) | 2023-12-22 | 2025-06-26 | Illumina, Inc. | Cellules d'écoulement réutilisables et leurs procédés d'utilisation pour le séquençage d'acides nucléiques |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2114748A (en) * | 1934-05-09 | 1938-04-19 | Firm Jenaer Glaswerk Schott & | Method of making porous filter bodies of particles of glass |
| US3433782A (en) * | 1965-12-27 | 1969-03-18 | Miles Lab | Separation and recovery of oligonucleotides |
| BE757291A (fr) * | 1969-10-10 | 1971-04-09 | Smith Kline French Lab | Complexe antiviral de arn et d'un polysaccharide |
| BE793826A (fr) * | 1972-10-24 | 1973-07-10 | Dainippon Pharmaceutical Co | Procede de purification d'une enzyme de cytolyse |
| US3935111A (en) * | 1973-04-06 | 1976-01-27 | Bentley Laboratories, Inc. | Device for removing blood microemboli |
| US3925600A (en) * | 1975-01-20 | 1975-12-09 | Bell Telephone Labor Inc | Line switching system for digital data |
| NO760938L (fr) * | 1975-03-22 | 1976-09-23 | Biotest Serum Institut Gmbh | |
| US4303530A (en) * | 1977-10-26 | 1981-12-01 | Medical Incorporated | Blood filter |
| JPS5598912A (en) * | 1979-01-23 | 1980-07-28 | Toray Ind Inc | Glucose-isomerizing fiber and its production |
| US4491660A (en) * | 1980-01-10 | 1985-01-01 | Abbott Laboratories | Matrix polymers for binding endotoxins |
| US4830969A (en) * | 1981-08-31 | 1989-05-16 | The Research Foundation Of State University Of New York | Process for the rapid and simple isolation of nucleic acids |
| DE3211309A1 (de) * | 1982-03-26 | 1983-09-29 | Metin Dipl.-Ing. 6100 Darmstadt Colpan | Chromatographisches verfahren zur isolierung von makromolekuelen |
| US4483920A (en) * | 1982-05-17 | 1984-11-20 | Hahnemann University | Immobilization of message RNA directly from cells onto filter material |
| US4734192A (en) * | 1982-07-01 | 1988-03-29 | Millipore Corporation | Multiwell membrane filtration apparatus |
| US4427580A (en) * | 1982-09-01 | 1984-01-24 | Cornell Research Foundation, Inc. | Method for separation and recovery of proteins and nucleic acids from nucleoproteins using water destructuring salts |
| DE3308932A1 (de) * | 1983-03-12 | 1984-09-13 | Hoechst Ag, 6230 Frankfurt | Verfahren zur abtrennung von ribonukleinsaeuren aus einer loesung, die desoxyribonukleinsaeuren enthaelt |
| NZ210501A (en) * | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
| US6492107B1 (en) * | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
| WO1986005803A1 (fr) * | 1985-03-30 | 1986-10-09 | Marc Ballivet | Procede d'obtention d'adn, arn, peptides, polypeptides ou proteines, par une technique de recombinaison d'adn |
| US5091309A (en) * | 1986-01-16 | 1992-02-25 | Washington University | Sindbis virus vectors |
| US6027750A (en) * | 1986-09-04 | 2000-02-22 | Gautsch; James | Systems and methods for the rapid isolation of nucleic acids |
| US5750338A (en) * | 1986-10-23 | 1998-05-12 | Amoco Corporation | Target and background capture methods with amplification for affinity assays |
| DE3639949A1 (de) * | 1986-11-22 | 1988-06-09 | Diagen Inst Molekularbio | Verfahren zur trennung von langkettigen nukleinsaeuren |
| US5422251A (en) * | 1986-11-26 | 1995-06-06 | Princeton University | Triple-stranded nucleic acids |
| US4935342A (en) * | 1986-12-01 | 1990-06-19 | Syngene, Inc. | Method of isolating and purifying nucleic acids from biological samples |
| US4833239A (en) * | 1987-01-29 | 1989-05-23 | Genetics Institute, Inc. | Method for the isolation and purification of DNA molecules |
| US4921805A (en) * | 1987-07-29 | 1990-05-01 | Life Technologies, Inc. | Nucleic acid capture method |
| US4923978A (en) * | 1987-12-28 | 1990-05-08 | E. I. Du Pont De Nemours & Company | Process for purifying nucleic acids |
| US4973551A (en) * | 1988-01-15 | 1990-11-27 | Merck & Co., Inc. | Vector for the expression of fusion proteins and protein immunogens |
| US4921952A (en) * | 1988-01-21 | 1990-05-01 | The United States Of America As Represented By The United States Department Of Energy | Nucleic acid isolation process |
| US5496562A (en) * | 1988-10-05 | 1996-03-05 | Flinders Technologies Pty Ltd | Solid medium and method for DNA storage |
| US5807527A (en) * | 1991-05-29 | 1998-09-15 | Flinders Technologies Pty. Ltd. | Solid medium and method for DNA storage |
| US5756126A (en) * | 1991-05-29 | 1998-05-26 | Flinders Technologies Pty. Ltd. | Dry solid medium for storage and analysis of genetic material |
| US5217879A (en) * | 1989-01-12 | 1993-06-08 | Washington University | Infectious Sindbis virus vectors |
| US4948561A (en) * | 1989-02-09 | 1990-08-14 | Eastman Kodak Company | Multiple level filter device and kit containing same |
| US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5234809A (en) * | 1989-03-23 | 1993-08-10 | Akzo N.V. | Process for isolating nucleic acid |
| DE68914689T2 (de) * | 1989-05-22 | 1994-10-27 | Genetics Inst | Verbesserte zusammensetzung zur isolierung und anreicherung von nukleinsäure und dadurch verbessertes verfahren. |
| US5166057A (en) * | 1989-08-28 | 1992-11-24 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand rna virus expression-systems |
| US4997932A (en) * | 1989-11-13 | 1991-03-05 | Boehringer Mannheim Corporation | Method and kit for purifying nucleic acids |
| US5458878A (en) * | 1990-01-02 | 1995-10-17 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | P. exotoxin fusio proteins have COOHG220101al alterations which increase cytotoxicity |
| US5652141A (en) * | 1990-10-26 | 1997-07-29 | Oiagen Gmbh | Device and process for isolating nucleic acids from cell suspension |
| US5234824A (en) * | 1990-11-13 | 1993-08-10 | Specialty Laboratories, Inc. | Rapid purification of DNA |
| US5187083A (en) * | 1990-11-13 | 1993-02-16 | Specialty Laboratories, Inc. | Rapid purification of DNA |
| DE4143639C2 (de) * | 1991-12-02 | 2002-10-24 | Qiagen Gmbh | Verfahren zur Isolierung und Reinigung von Nukleinsäuren |
| US5438128A (en) * | 1992-02-07 | 1995-08-01 | Millipore Corporation | Method for rapid purifiction of nucleic acids using layered ion-exchange membranes |
| EP0555798B1 (fr) * | 1992-02-13 | 1999-05-06 | Becton, Dickinson and Company | Célite hydrate et purification d'ADN |
| US5401632A (en) * | 1992-07-16 | 1995-03-28 | Wisconsin Alumni Research Foundation | Triple helix purification and sequencing |
| US5591841A (en) * | 1993-01-14 | 1997-01-07 | Ji; Huamin | Rapid purification of circular DNA by triplex-mediated affinity capture |
| US5482836A (en) * | 1993-01-14 | 1996-01-09 | The Regents Of The University Of California | DNA purification by triplex-affinity capture and affinity capture electrophoresis |
| AU689815B2 (en) * | 1993-08-30 | 1998-04-09 | Promega Corporation | Nucleic acid purification compositions and methods |
| US6015686A (en) * | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| US6043032A (en) * | 1993-09-22 | 2000-03-28 | Tosoh Corporation | Method of extracting nucleic acids and method of detecting specified nucleic acid sequences |
| US5990301A (en) * | 1994-02-07 | 1999-11-23 | Qiagen Gmbh | Process for the separation and purification of nucleic acids from biological sources |
| DE4403940A1 (de) * | 1994-02-08 | 1995-08-10 | Genomed Molekularbiologische U | Chromatographiematerial |
| US5532154A (en) * | 1994-03-21 | 1996-07-02 | Research Development Foundation | Mutated alpha virus |
| US6037465A (en) * | 1994-06-14 | 2000-03-14 | Invitek Gmbh | Universal process for isolating and purifying nucleic acids from extremely small amounts of highly contaminated various starting materials |
| US5601711A (en) * | 1994-10-31 | 1997-02-11 | Gelman Sciences Inc. | Selective separation filter device |
| US5792462A (en) * | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
| CA2223896A1 (fr) * | 1995-06-08 | 1996-12-27 | Robert Hugh Don | Procede et appareil d'extraction d'adn |
| US5804684A (en) * | 1995-08-24 | 1998-09-08 | The Theobald Smith Research Institute, Inc. | Method for isolating nucleic acids |
| US5833860A (en) * | 1995-08-28 | 1998-11-10 | Millipore Investment Holdings Limited | Centrifugal adsorptive sample preparation device and method |
| DE19612650C1 (de) * | 1996-04-02 | 1997-07-31 | Evotec Biosystems Gmbh | Verfahren zur Fluoreszenzmarkierung von Molekülen |
| US5665247A (en) * | 1996-09-16 | 1997-09-09 | Whatman Inc. | Process for sealing microplates utilizing a thin polymeric film |
| US6048457A (en) * | 1997-02-26 | 2000-04-11 | Millipore Corporation | Cast membrane structures for sample preparation |
| US5970782A (en) * | 1997-05-16 | 1999-10-26 | Life Technologies, Inc. | Gradient filtration apparatus |
| US6268133B1 (en) * | 1997-06-25 | 2001-07-31 | Invitrogen Corporation | Method for isolating and recovering target DNA or RNA molecules having a desired nucleotide sequence |
| US6103195A (en) * | 1997-08-08 | 2000-08-15 | Shukla; Ashok K. | Micro-volume spin columns for sample preparation |
| US6221655B1 (en) * | 1998-08-01 | 2001-04-24 | Cytosignal | Spin filter assembly for isolation and analysis |
| EP1141234A4 (fr) * | 1999-01-06 | 2004-05-19 | Invitrogen Corp | Procedes et compositions permettant d'isoler des molecules d'acide nucleique |
| GB2347077A (en) * | 1999-02-27 | 2000-08-30 | Tsay Jenn Long | Combination desk and chair |
| EP1173744A4 (fr) * | 1999-03-02 | 2002-10-16 | Qualigen Inc | Procedes et appareil de separation de fluides biologiques |
| NZ524065A (en) * | 2000-07-18 | 2005-02-25 | Invitrogen Corp | Device and methods for subdividing and filtering gel material and extracting molecules therefrom |
| JP2004518421A (ja) * | 2000-12-12 | 2004-06-24 | インビトロジェン コーポレイション | 固体マトリックスから核酸分子を解放させるための組成物および方法 |
| WO2002065125A1 (fr) * | 2001-02-13 | 2002-08-22 | Invitrogen Corporation | Procedes et compositions utilises dans l'isolation de macromolecules biologiques |
-
2001
- 2001-07-13 US US09/903,864 patent/US20020012982A1/en not_active Abandoned
- 2001-07-13 AU AU2001273432A patent/AU2001273432A1/en not_active Abandoned
- 2001-07-13 NZ NZ523831A patent/NZ523831A/en unknown
- 2001-07-13 CA CA002415713A patent/CA2415713A1/fr not_active Abandoned
- 2001-07-13 WO PCT/US2001/022080 patent/WO2002006456A1/fr not_active Ceased
- 2001-07-13 JP JP2002512349A patent/JP2004504330A/ja active Pending
- 2001-07-13 EP EP01952705A patent/EP1301591A4/fr not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111818980A (zh) * | 2018-03-08 | 2020-10-23 | 生物辐射实验室股份有限公司 | 阴离子交换-疏水混合模式色谱树脂 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2415713A1 (fr) | 2002-01-24 |
| JP2004504330A (ja) | 2004-02-12 |
| EP1301591A4 (fr) | 2004-05-26 |
| EP1301591A1 (fr) | 2003-04-16 |
| NZ523831A (en) | 2005-10-28 |
| WO2002006456A1 (fr) | 2002-01-24 |
| US20020012982A1 (en) | 2002-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20020012982A1 (en) | Methods and compositions for rapid protein and peptide extraction and isolation using a lysis matrix | |
| AU740145B2 (en) | Endotoxin reduction in nucleic acid purification | |
| AU774810B2 (en) | Mixed-bed solid phase and its use in the isolation of nucleic acids | |
| KR100623184B1 (ko) | 임의의 복잡한 출발물질로부터 핵산을 분리하기 위한배합물과 방법 그리고 복합한 유전자 분석법 | |
| US6787307B1 (en) | Lysate clearance and nucleic acid isolation using silanized silica matrices | |
| JP4175670B2 (ja) | 固体相核酸の単離 | |
| JP3115324B2 (ja) | 核酸を単離する装置及び方法 | |
| JP2564335B2 (ja) | 生体試料から核酸を単離し精製する方法 | |
| US9410145B2 (en) | Method for the isolation of nucleic acids | |
| JPH08501321A (ja) | クロマトグラフィーによる核酸混合物の精製分離法 | |
| US7319021B2 (en) | Cell lysis composition, methods of use, apparatus and kit | |
| EP1173559A1 (fr) | Procede de purification d'acides nucleiques a l'aide de carbure de silicium | |
| JP2006523463A (ja) | 固体支持体を使用してrnaを精製するための、組成物および方法 | |
| JP2004501054A (ja) | 核酸の単離 | |
| WO2000040697A1 (fr) | Procedes et compositions permettant d'isoler des molecules d'acide nucleique | |
| AU2002225942B2 (en) | Lysate clearance and nucleic acid isolation using silanized silica matrices | |
| JP2003524157A (ja) | クロマトグラフィー材料及びその使用方法 | |
| CA2315257A1 (fr) | Procede d'isolement d'acides nucleiques a chaine courte et a chaine longue | |
| JP2008506654A (ja) | 陽イオン洗浄剤を使用した核酸を洗浄および単離するための方法 | |
| MXPA98007681A (en) | Methods of isolating biological target materials using silica magnetic particles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |